Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 6/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467029 | 0.85 | VCAM1 (0.56) | VCAM1NPBWR1MCHR1KMT2AMCOLN3 | |
| SCHEMBL2996937 | 0.84 | KMT2A (0.47) | KMT2AMEN1ATMALDH1A1MAPT | |
| SCHEMBL2999492 | 0.83 | VCAM1 (0.52) | VCAM1NPBWR1MCHR1KMT2AMCOLN3 | |
| SCHEMBL2985916 | 0.83 | KMT2A (0.71) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL5461806 | 0.80 | TP53 (0.56) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL2998796 | 0.80 | KMT2A (0.67) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL5461695 | 0.79 | KMT2A (0.66) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL2994962 | 0.78 | KMT2A (0.42) | KMT2AMEN1ATMALDH1A1MAPT | |
| SCHEMBL5466708 | 0.76 | VCAM1 (0.56) | VCAM1NPBWR1MCHR1KMT2AMEN1 | |
| SCHEMBL5473761 | 0.76 | KMT2A (0.70) | VCAM1NPBWR1MCHR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507536-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8263588-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2008124614-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | VCAM1 4437/4885NPBWR1 50/4885MCHR1 49/4885 |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | VCAM1 4437/4885NPBWR1 50/4885MCHR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.